New derivatives of (1H-Indol-3-Ilmethyl) Dimethylamine with blocking activity of voltage-dependent Ca2 + channels, preferably NO-L, and their application in the treatment of diseases of the nervous system
FUNDACION PARA LA INVESTIGACION BIOMEDICA DEL HOSPITAL UNIVERSITARIO DE LA PRINCESA;UNIVERSIDAD AUTONOMA DE MADRID;FUNDACION TEOFILO HERNANDO
发明人:
LAJARIN CUESTA, Rocío,ARRANZ TAGARRO, Juan Alberto,PEREZ DE NANCLARES, Carmen,GANDIA JUAN, Luis,GARCIA GARCIA, Antonio,DE LOS RIOS SALGADO, Cristóbal
申请号：
ES201500354
公开号：
ES2589599B1
申请日:
2015.05.14
申请国别(地区):
ES
年份:
2017
代理人:
摘要：
New derivatives of (1H-INDOL-3-ILMETIL) Dimethylamine with blocking activity of the voltage-dependent Ca {sup, 2 +} channels, preferably NO-L, and their application in the treatment of diseases of the nervous system. # { IMAGE-01} #The present invention relates to compounds of general formula (I), and their use in the manufacture of medicaments useful for the treatment of diseases of the central and peripheral nervous system, such as neurodegenerative diseases, stroke, epilepsy , migraine, neuropathic pain or, in general, any disease caused by the alteration of the biological functions on which these products act. One of the therapeutic strategies to treat these diseases is the reduction of Ca {sup, 2 +} input through voltage-dependent Ca {sup, 2 +} (CCDV) channels. Thus, the compounds claimed in this invention regulate the homeostasis of Ca {sup, 2 +} in excitable cells, which is altered in these conditions. Among all types of CCDV, the compounds of general formula (I) preferably act by the so-called non-L, so they would lack peripheral side effects of hemodynamic type, where CCDV type L are predominant. The present invention can be framed in the field of the pharmaceutical industry.Nuevos derivados de (1H-INDOL-3-ILMETIL) Dimetilamina con actividad bloqueador de los canales de Ca{sup,2+} dependientes de voltaje, preferentemente NO-L, y su aplicación en el tratamiento de enfermedades del sistema nervioso.#{IMAGEN-01}#La presente invención se refiere a compuestos de fórmula general (I), y su uso en la manufactura de medicamentos útiles para el tratamiento de enfermedades del sistema nervioso central y periférico, como las enfermedades neurodegenerativas, el ictus, la epilepsia, la migraña, dolor neuropático o, en general, cualquier enfermedad producida por la alteración de las funciones biológicas sobre las que actúan dichos productos. Una de las estrategias terapéuticas para tratar estas enfermedades es la reducción de la entrada de Ca{sup,2+} a través de canales d
